Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4679491 | 0.81 | — | — | |
| SCHEMBL4277857 | 0.78 | CHRNB2 (0.31) | — | |
| SCHEMBL303322 | 0.78 | — | — | |
| SCHEMBL2067545 | 0.73 | LMNA (0.41) | — | |
| SCHEMBL3525467 | 0.71 | — | — | |
| SCHEMBL18043744 | 0.69 | SLC6A4 (0.32) | — | |
| SCHEMBL2066866 | 0.69 | — | — | |
| SCHEMBL2565204 | 0.69 | — | — | |
| SCHEMBL646821 | 0.68 | — | — | |
| SCHEMBL1569600 | 0.68 | TRPA1 (0.38) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438063-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010139747-A1 | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
| EP-1625119-B1 | SUBSTITUTED-1-PHTHALAZINAMINES AS VR-1 ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-7329659-B2 | Substituted-1-phthalazinamines as vr-1 antagonists | MERCK SHARP & DOHME LIMITED (GB) | 2008-02-12 | — | — | US | disclosed |
| US-20060229307-A1 | Substituted-1-phthalazinamines as vr-1 antagonists | MERCK SHARP & DOHME LTD. (GB) | 2006-10-12 | — | — | US | disclosed |
| EP-1625119-A1 | SUBSTITUTED-1-PHTHALAZINAMINES AS VR-1 ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004099177-A1 | SUBSTITUTED-1-PHTHALAZINAMINES AS VR-1 ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | PRKCA, ABL1, MYLK2 | TRPA1 3927/4885 |
| US-20060229307-A1 | Substituted-1-phthalazinamines as vr-1 antagonists | TRPV1, ARRB1, AVPR1A | TRPA1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.